Cirilo, PDRREFERÊNCIAS209Baker ME. Evolution of 17 beta-hydroxysteroid <strong>de</strong>hydrogenases and their role in androgen,estrogen and retinoid action. Mol Cell Endocrinol, 171, 211-215, 2001.Barbieri RL and An<strong>de</strong>rsen J. Uterine leiomyomas. The somatic mutation theory. Sem ReprodEndocrinol, 10, 301-309, 1992.Bayani J and Squire JA. Comparative genomic hybridization. Curr Protoc Cell Biol, Chapter 22, Unit22.6, 2005.Bayani J, Marrano P, Graham C. Genomic instability and copy-number heterogeneity of chromosome19q, including the kallikrein locus, in ovarian carcinomas. Mol Oncol, 5, 48-60, 2011.Behera MA, Feng L, Yonish B et al. Thrombospondin-1 and Thrombospondin-2 mRNA and TSP-1and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 andCOL3A1 and to the collagen cross-link ydroxyproline. Reprod Sci, 14, 63-76, 2007.Beheshti B, Park PC, Brau<strong>de</strong> I et al. Microarray CGH. Methods Mol Biol, 204, 191-207, 2002.Beroukhim R, Getz G, Nghiemphu L et al. Assessing the significance of chromosomal aberrations incancer: methodology and application to glioma. PNAS, 104, 20007-20012, 2007.Bhi<strong>de</strong> RS, Lombardo LJ, Hunt JT et al. The antiangiogenic activity in xenograft mo<strong>de</strong>ls of brivanib, adual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factorreceptor-1 kinases. Mol Cancer Ther, 9, 369-378, 2010.Bisognin A, Coppe A, Ferrari F et al. A-MADMAN: annotation-based microarray data meta-analysistool. BMC Bioinformatics, 10, 201, 2009.Bisso A, Collavin L, Del Sal G. p73 as a Pharmaceutical Target for Cancer Therapy Curr Pharm Des,Epub ahead of print, 2011.Bodner-Adler B, Bodner K, Czerwenka K et al. Expression of p16 protein in patients with uterinesmooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol, 96, 62-66, 2005.Bonatz G, Frahm SO, Andreas S et al. Telomere shortening in uterine leiomyomas. Am J ObstetGynecol, 179, 591-596, 1998.Bonazzi VF, Irwin D, Hayward NK. I<strong>de</strong>ntification of candidate tumor suppressor genes inactivatedby promoter methylation in melanoma. Genes Chromosomes Cancer, 48, 10-21, 2009.Borsari R, Bozzini N, Junqueira CR, et al. Genic expression of the uterine leiomyoma inreproductive-aged women after treatment with goserelin. Fertil Steril, 94, 1072-1077, 2010.Boveri T. Zur Frage <strong>de</strong>r Entstehung maligner Tumoren. (Fischer, Jena, G.D.R.), 1914.Bow<strong>de</strong>n W, Skorupski J, Kovanci E et al. Detection of novel copy number variants in uterineleiomyomas using high-resolution SNP arrays. Mol Hum Reprod, 15, 563-568, 2009.Bozzini N, Rodrigues CJ, Petti DA et al. Effects of treatment with gonadotropin releasing hormoneagonist on the uterine leiomyomata structure. Acta Obstet Gynecol Scand, 82, 330-334, 2003.
Cirilo, PDRREFERÊNCIAS210Brazelle W, Kreahling JM, Gemmer J et al. Histone <strong>de</strong>acetylase inhibitors downregulate checkpointkinase 1 expression to induce cell <strong>de</strong>ath in non-small cell lung cancer cells. PLoS One, 5,e14335, 2010.Bridges CB. The Bar‘s gene: a duplication. Science, 83, 210–211, 1936.Brosens I, Deprest J, Dal Cin P et al. Clinical significance of cytogenetic abnormalities in uterinemyomas. Fertil Steril, 69, 232-235, 1998.Buckanovich RJ, Posner JB, Darnell RB. Nova, the paraneoplastic Ri antigen, is homologous to anRNA-binding protein and is specifically expressed in the <strong>de</strong>veloping motor system. Neuron,11, 657–672, 1993.Burroughs KD, Howe SR, Okubo Y et al. Dysregulation of IGF-I signaling in uterine leiomyoma. JEndocrinol, 172, 83-93, 2002.Cai J, Jiang Y, Zhang Y. Quantitation of Ras p21 oncogene and DNA content of gastrointestinalsmooth muscle tumors and prognostic significance. Zhonghua Wai Ke Za Zhi, 33, 225-228,1995.Cai YR, Diao XL, Wang SF et al. X-chromosomal inactivation analysis of uterine leiomyomas revealsa common clonal origin of different tumor nodules in some multiple leiomyomas. Int J Oncol,31, 1379-1389, 2007.Caldas C and Brenton JD. Sizing up miRNAs as cancer genes. Nat Med, 11, 712-714, 2005.Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragilesites and genomic regions involved in cancers. Proc Natl Acad Sci, 2999-3004, 2004.Canevari RA, Pontes A, Rosa FE et al. In<strong>de</strong>pen<strong>de</strong>nt clonal origin of multiple uterine leiomyomas thatwas <strong>de</strong>termined by X chromosome inactivation and microsatellite analysis. Am J ObstetGynecol, 193, 1395–1403, 2005a.Canevari RA, Pontes A, Rogatto SR. Microallelotyping Defines Novel Regions of Loss ofHeterozygosity in Uterine Leiomyomas. Molecular Carcinogenesis, 42, 177–182, 2005b.Canevari, RA and Rogatto SR. Uterine Leiomyoma: Updates in Cytogenetics and Molecular Analysis.Asian Journal of Cancer, 6, 15-28, 2007.Carter, NP. Methods and strategies for analyzing copy number variation using DNA microarrays.Nat Genet, 39, S16–S21, 2007.Carvalho B, Marques CJ, Carvalho D et al. Novel human pathological mutations. Gene symbol:CYP21A2. Disease: Adrenal Hyperplasia. Hum Genet, 127, 482-483, 2010.Castillo SD, Angulo B, Suarez-Gauthier A et al. Gene amplification of the transcription factor DP1and CTNND1 in human lung cancer. J Pathol, 222, 89-98, 2010.Catherino WH, Prupas C, Tsibris JC et al. Strategy for elucidating differentially expressed genes inleiomyomata i<strong>de</strong>ntified by microarray technology. Fertil Steril, 80, 282-290, 2003.
- Page 1 and 2:
Universidade Estadual Paulista “J
- Page 3:
AGRADECIMENTOSÀ minha orientadora
- Page 10 and 11:
LISTA DE FIGURASFigura 1 A - Freqü
- Page 12 and 13:
sonda A_14_P131252 que mapeia o gen
- Page 14 and 15:
esultante da análise do SAM (Tushe
- Page 16 and 17:
Figura 33 Agrupamento hierárquico
- Page 18 and 19:
LISTA DE TABELASQuadro 1Relação d
- Page 20 and 21:
LISTA DE SIGLAS E ABREVIATURASANG A
- Page 22 and 23:
SUMÁRIO1 Introdução ............
- Page 24 and 25:
Cirilo, PDRINTRODUÇÃO11. Introdu
- Page 26 and 27:
Cirilo, PDRINTRODUÇÃO3dados em li
- Page 28 and 29:
Cirilo, PDRINTRODUÇÃO5infertilida
- Page 30 and 31:
Cirilo, PDRINTRODUÇÃO7foram despe
- Page 32 and 33:
Cirilo, PDRINTRODUÇÃO9(10q24.33),
- Page 34 and 35:
Cirilo, PDRINTRODUÇÃO11somente fo
- Page 36 and 37:
Cirilo, PDRINTRODUÇÃO13Segundo a
- Page 38 and 39:
Cirilo, PDRINTRODUÇÃO15(Sargent e
- Page 40 and 41:
Cirilo, PDRINTRODUÇÃO171 geralmen
- Page 42 and 43:
Cirilo, PDRINTRODUÇÃO19transcrita
- Page 44 and 45:
Cirilo, PDRINTRODUÇÃO21amostras.
- Page 46 and 47:
Cirilo, PDRINTRODUÇÃO23evento que
- Page 48 and 49:
Cirilo, PDRINTRODUÇÃO25também os
- Page 50 and 51:
Cirilo, PDRINTRODUÇÃO27tratamento
- Page 52 and 53:
Cirilo, PDRINTRODUÇÃO29Hodge et a
- Page 54 and 55:
Cirilo, PDRMATERIAL E MÉTODOS313.
- Page 56 and 57:
Cirilo, PDRMATERIAL E MÉTODOS33Tam
- Page 58 and 59:
Cirilo, PDRMATERIAL E MÉTODOS35for
- Page 60 and 61:
Cirilo, PDRMATERIAL E MÉTODOS370,1
- Page 62 and 63:
Cirilo, PDRMATERIAL E MÉTODOS39alt
- Page 64 and 65:
Cirilo, PDRMATERIAL E MÉTODOS413)
- Page 66 and 67:
Cirilo, PDRRESULTADOS43Tabela 1. Da
- Page 68 and 69:
Cirilo, PDRRESULTADOS45ABFigura 1.
- Page 70 and 71:
Cirilo, PDRRESULTADOS47Este estudo
- Page 72 and 73:
Cirilo, PDRRESULTADOS494.2.1 Caract
- Page 74 and 75:
Cirilo, PDRRESULTADOS51Entre as 45
- Page 76 and 77:
Cirilo, PDRRESULTADOS53(10%)Cromoss
- Page 78 and 79:
Cirilo, PDRRESULTADOS55Cromossomo 1
- Page 80 and 81:
Cirilo, PDRRESULTADOS574.2.2 Tumore
- Page 82 and 83:
Cirilo, PDRRESULTADOS59Tabela 4. De
- Page 84 and 85:
Cirilo, PDRRESULTADOS61629T 629T_A,
- Page 86 and 87:
Cirilo, PDRRESULTADOS63279,263-1,48
- Page 88 and 89:
Cirilo, PDRRESULTADOS65ABFigura 7.
- Page 90 and 91:
Cirilo, PDRRESULTADOS67ABFigura 8 -
- Page 92 and 93:
ABCirilo, PDRRESULTADOS69Figura 10.
- Page 94 and 95:
Cirilo, PDRRESULTADOS71Figura 11. A
- Page 96 and 97:
Cirilo, PDRRESULTADOS73Grupo 1tumor
- Page 98 and 99:
Cirilo, PDRRESULTADOS75Figura 14. A
- Page 100 and 101:
Cirilo, PDRRESULTADOS77631T_C 99,55
- Page 102 and 103:
Cirilo, PDRRESULTADOS794.3 Análise
- Page 104 and 105:
Cirilo, PDRRESULTADOS81Tabela 7. Re
- Page 106 and 107:
ABCirilo, PDRRESULTADOS83Figura 16.
- Page 108 and 109:
Cirilo, PDRRESULTADOS85Figura 17. V
- Page 110 and 111:
Cirilo, PDRRESULTADOS87Figura 19. R
- Page 112 and 113:
Cirilo, PDRRESULTADOS894.3.1 Análi
- Page 114 and 115:
Cirilo, PDRRESULTADOS91Figura 22. A
- Page 116 and 117:
Cirilo, PDRRESULTADOS93Entre os cas
- Page 118 and 119:
Cirilo, PDRRESULTADOS95Figura 23. A
- Page 120 and 121:
Cirilo, PDRRESULTADOS97Tabela 8. Ge
- Page 122 and 123:
Cirilo, PDRRESULTADOS99HAPLN1 HAPLN
- Page 124 and 125:
Cirilo, PDRRESULTADOS101beta 4MYO10
- Page 126 and 127:
Cirilo, PDRRESULTADOS103DIO1 DIO1 d
- Page 128 and 129:
Cirilo, PDRRESULTADOS105inhibits CD
- Page 130 and 131:
Cirilo, PDRRESULTADOS107CENPK CENPK
- Page 132 and 133:
Cirilo, PDRRESULTADOS109pareamento
- Page 134 and 135:
Cirilo, PDRRESULTADOS111JUB, ↓MAG
- Page 136 and 137:
Cirilo, PDRRESULTADOS113Figura 25.
- Page 138 and 139:
Cirilo, PDRRESULTADOS115Figura 27.
- Page 140 and 141:
Cirilo, PDRRESULTADOS117Figura 29.
- Page 142 and 143:
Cirilo, PDRRESULTADOS1194.5.1 CGH a
- Page 144 and 145:
Cirilo, PDRRESULTADOS121Figura 32.
- Page 146 and 147:
Cirilo, PDRRESULTADOS123Tabela 10.
- Page 148 and 149:
Cirilo, PDRRESULTADOS125
- Page 150 and 151:
Cirilo, PDRRESULTADOS1274.5.3.1 Pre
- Page 152 and 153:
Cirilo, PDRRESULTADOS129PKP3 - -PRE
- Page 154 and 155:
Cirilo, PDRRESULTADOS131Tabela 12.
- Page 156 and 157:
Cirilo, PDRRESULTADOS133Perda (1) N
- Page 158 and 159:
ABCirilo, PDRRESULTADOS135Figura 33
- Page 160 and 161:
Cirilo, PDRRESULTADOS1374.5.3.4 Fre
- Page 162 and 163:
Cirilo, PDRRESULTADOS139Tabela 13.
- Page 164 and 165:
Cirilo, PDRRESULTADOS1414.5.3.6 An
- Page 166 and 167:
Cirilo, PDRRESULTADOS143Tabela 15.
- Page 168 and 169:
Cirilo, PDRRESULTADOS145ativação
- Page 170 and 171:
ACirilo, PDRRESULTADOS147BFigura 36
- Page 172 and 173:
Cirilo, PDRRESULTADOS149Figura 38.
- Page 174 and 175:
Cirilo, PDRDISCUSSÃO1515. Discuss
- Page 177 and 178:
Cirilo, PDRDISCUSSÃO154informaçõ
- Page 179 and 180:
Cirilo, PDRDISCUSSÃO156descritos g
- Page 181 and 182: Cirilo, PDRDISCUSSÃO158uma proteí
- Page 183 and 184: Cirilo, PDRDISCUSSÃO160celulares e
- Page 185 and 186: Cirilo, PDRDISCUSSÃO162apresentado
- Page 187 and 188: Cirilo, PDRDISCUSSÃO164q14). Porta
- Page 189 and 190: Cirilo, PDRDISCUSSÃO166Desde 1991,
- Page 191 and 192: Cirilo, PDRDISCUSSÃO168núcleo das
- Page 193 and 194: Cirilo, PDRDISCUSSÃO170sobre LHFPL
- Page 195 and 196: Cirilo, PDRDISCUSSÃO172outras cate
- Page 197 and 198: Cirilo, PDRDISCUSSÃO174Entre as ou
- Page 199 and 200: Cirilo, PDRDISCUSSÃO176regiões de
- Page 201 and 202: Cirilo, PDRDISCUSSÃO178da RNA Pol
- Page 203 and 204: Cirilo, PDRDISCUSSÃO180proliferati
- Page 205 and 206: Cirilo, PDRDISCUSSÃO182Entre os 20
- Page 207 and 208: Cirilo, PDRDISCUSSÃO184propôs um
- Page 209 and 210: Cirilo, PDRDISCUSSÃO186analisados
- Page 211 and 212: Cirilo, PDRDISCUSSÃO188observados
- Page 213 and 214: Cirilo, PDRDISCUSSÃO190moduladores
- Page 215 and 216: Cirilo, PDRDISCUSSÃO192genômica/d
- Page 217 and 218: Cirilo, PDRDISCUSSÃO194identificar
- Page 219 and 220: Cirilo, PDRDISCUSSÃO196e também d
- Page 221 and 222: Cirilo, PDRDISCUSSÃO198O gene COL3
- Page 223 and 224: Cirilo, PDRDISCUSSÃO200resistênci
- Page 225 and 226: Cirilo, PDRDISCUSSÃO202bioquímica
- Page 227 and 228: Cirilo, PDRDISCUSSÃO204carcinoma c
- Page 229 and 230: Cirilo, PDRCONCLUSÕES DISCUSSÃO20
- Page 231: Cirilo, PDRREFERÊNCIAS2087. Refer
- Page 235 and 236: Cirilo, PDRREFERÊNCIAS212Churikov
- Page 237 and 238: Cirilo, PDRREFERÊNCIAS214Gannon BR
- Page 239 and 240: Cirilo, PDRREFERÊNCIAS216Holthause
- Page 241 and 242: Cirilo, PDRREFERÊNCIAS218Kazmiercz
- Page 243 and 244: Cirilo, PDRREFERÊNCIAS220Lloret M,
- Page 245 and 246: Cirilo, PDRREFERÊNCIAS222Mitra R,
- Page 247 and 248: Cirilo, PDRREFERÊNCIAS224Ozisik YY
- Page 249 and 250: Cirilo, PDRREFERÊNCIAS226Redon R,
- Page 251 and 252: Cirilo, PDRREFERÊNCIAS228Solyom S,
- Page 253 and 254: Cirilo, PDRREFERÊNCIAS230Ueki K, R
- Page 255 and 256: Cirilo, PDRREFERÊNCIAS232and poly(
- Page 257 and 258: Skubitz KM e Skubitz APJ Lab Clin M
- Page 259 and 260: Dimitrova IK et al. Fertil Steril,9
- Page 261 and 262: 317T_B317T_C13 614T 44 LU prolifera
- Page 263 and 264: 46 867T 46 LUM outros B 14 33,5 17
- Page 265 and 266: 1015T 6q13-q14.1 75,806,978-76,314,
- Page 267 and 268: MRPS31, SLC25A15, SUGT1L1 320d-1630
- Page 269 and 270: 8q22.3-q23.1 105,831,966 107,742,33
- Page 271 and 272: Anexo 5. Genes identificados na an
- Page 273 and 274: + + CCDC8 0 51 37 14+ - CALM3 51 0
- Page 275 and 276: ABSTRACTBackground: Uterine leiomyo
- Page 277 and 278: Thus, these findings prompt us to i
- Page 279 and 280: Technologies, Santa Clara, CA). Sta
- Page 281 and 282: mapped at 1p36.13, 1q41, 2q32.1, 2q
- Page 283 and 284:
genetic disorder showed the higher
- Page 285 and 286:
The modulators were mainly associat
- Page 287 and 288:
egulation of cell cycle. Chegini an
- Page 289 and 290:
REFERENCES[1] Baird DD, Dunson DB (
- Page 291 and 292:
[37] Luo X, Ding L, Xu J et al. (20
- Page 293 and 294:
AArray CGHExpression arrayBtumoral
- Page 295 and 296:
ABDiseases and Disorders P value Mo
- Page 298 and 299:
Tabel 2. Genes identified on module
- Page 300 and 301:
Table S1. Clinical parameters and h
- Page 302 and 303:
32 954T 45 M secretory W 12 33,7 18
- Page 304 and 305:
16 28184420-30915100 2730680 p11.2
- Page 306 and 307:
MYPN hsa-miR-214 -NFKBIL2 - -PKP3 -
- Page 308:
Table S5. Ingenuity Pathways Analys